Indacaterol on dyspnea in chronic obstructive pulmonary disease: A systematic review and meta-analysis of randomized placebo-controlled trials

BMC Pulmonary Medicine

Volumn 13, Issue 1, 2013, Pages

  Han, Jiangna ^a   Dai, Lu ^b   Zhong, Nanshan ^c  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b Beijing SL Pharmaceutical Co Ltd   (China)

^c GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Baseline dyspnea index; Breathlessness; COPD; Meta analysis; Transition dyspnea index

Indexed keywords

INDACATEROL; PLACEBO; SALMETEROL; TIOTROPIUM BROMIDE;

ARTICLE; BASELINE DYSPNEA INDEX; CHRONIC OBSTRUCTIVE LUNG DISEASE; DYSPNEA; EMBASE; HUMAN; MEDLINE; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT PARAMETERS; TRANSITION DYSPNEA INDEX; TREATMENT RESPONSE;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; DYSPNEA; HUMANS; INDANS; PLACEBOS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84876988251     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/1471-2466-13-26     Document Type: Article

References (31)

1. Global Initiative for Obstructive Lung Disease (GOLD) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2011, http://www.goldcopd.org/Guidelines/guidelines-gold-summary-2011.html, Global Initiative for Obstructive Lung Disease (GOLD).
2. Qaseem A, Wilt TJ, Weinberger SE, Hanania NA, Criner G, van der Molen T, Marciniuk DD, Denberg T, Schünemann H, Wedzicha W, MacDonald R, Shekelle P. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011, 155:179-191.
3. Mahler DA, Selecky PA, Harrod CG, Benditt JO, Carrieri-Kohlman V, Curtis JR, Manning HL, Mularski RA, Varkey B, Campbell M, Carter ER, Chiong JR, Ely EW, Hansen-Flaschen J, O'Donnell DE, Waller A. American College of Chest Physicians consensus statement on the management of dyspnea in patients with advanced lung or heart disease. Chest 2010, 137:674-691. 10.1378/chest.09-1543, 20202949.
4. Balint B, Watz H, Amos C, Owen R, Higgins M, Kramer B. Onset of action of indacaterol in patients with COPD: Comparison with salbutamol and salmeterol-fluticasone. Int J Chron Obstruct Pulmon Dis 2010, 5:311-318. 2939686, 20856830.
5. Donohue JF, Fogarty C, Lötvall J, Mahler DA, Worth H, Yorgancioglu A, Iqbal A, Swales J, Owen R, Higgins M, Kramer B. Once-daily bronchodilators for chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010, 182:155-162. 10.1164/rccm.200910-1500OC, 20463178.
6. Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, Bleasdale P, Owen R, Higgins M, Kramer B. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax 2010, 65:473-479. 10.1136/thx.2009.125435, 20522841.
7. Kornmann O, Dahl R, Centanni S, Dogra A, Owen R, Lassen C, Kramer B. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J 2011, 37:273-279. 10.1183/09031936.00045810, 20693243.
8. Gotfried MH, Kerwin EM, Lawrence D, Lassen C, Kramer B. Efficacy of indacaterol 75 μg once-daily on dyspnea and health status: results of two double-blind, placebo-controlled 12-week studies. COPD 2012, 9:1-8. 10.3109/15412555.2012.651935, 22292591.
9. Kinoshita M, Lee SH, Hang LW, Ichinose M, Hosoe M, Okino N, Prasad N, Kramer B, Fukuchi Y. Efficacy and safety of indacaterol 150 and 300 μg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled study. Respirology 2012, 17:379-389. 10.1111/j.1440-1843.2011.02107.x, 22122202.
10. Kerwin EM, Gotfried MH, Lawrence D, Lassen C, Kramer B. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies. Clin Ther 2011, 33:1974-1984. 10.1016/j.clinthera.2011.11.009, 22177371.
11. Celli BR, MacNee W, Agusti A, Anzueto A, Berg B, Buist AS, Calverley PMA, Chavannes N, Dillard T, Fahy B, Fein A, Heffner J, Lareau S, Meek P, Martinez F, McNicholas W, Muris J, Austegard E, Pauwels R, Rennard S, Rossi A, Siafakas N, Tiep B, Vestbo J, Wouters E, ZuWallack R. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004, 23:932-946. 10.1183/09031936.04.00014304, 15219010.
12. Global Initiative for Obstructive Lung Disease (GOLD) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2005, http://www.goldcopd.org/search.html?q=GOLD+2005+update&user, Global Initiative for Obstructive Lung Disease (GOLD).
13. Jones P, Lareau S, Mahler DA. Measuring the effects of COPD on the patient. Respir Med 2005, 99(Suppl B):S11-S18.
14. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984, 85:751-758. 10.1378/chest.85.6.751, 6723384.
15. Witek TJ, Mahler DA. Meaningful effect size and patterns of response of the transition dyspnea index. J Clin Epidemiol 2003, 56:248-255. 10.1016/S0895-4356(02)00589-9, 12725879.
16. Witek TJ, Mahler DA. Minimal important difference of the transition dyspnea index in a multinational clinical trial. Eur Respir J 2003, 21:267-272. 10.1183/09031936.03.00068503a, 12608440.
17. Mahler DA, Witek TJ. The MCID of the transition dyspnea index is a total score of one unit. COPD 2005, 2:99-103. 10.1081/COPD-200050666, 17136969.
18. DerSimonian R, Laird N. Meta-analysis in clinical trials. Contr Clin Trials 1986, 7:177-188.
19. Mosteller F, Colditz GA. Understanding research synthesis (meta-analysis). Annu Rev Publ Health 1996, 17:1-23.
20. Bates MN, Khalakdina A, Pai M, Chang L, Lessa F, Smith KR. Risk of tuberculosis from exposure to tobacco smoke: a systematic review and meta-analysis. Arch Intern Med 2007, 167:335-342. 10.1001/archinte.167.4.335, 17325294.
21. Barnes PJ, Pocock SJ, Magnussen H, Iqbal A, Kramer B, Higgins M, Lawrence D. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulm Pharmacol Ther 2010, 23:165-171. 10.1016/j.pupt.2010.01.003, 20080201.
22. Vogelmeier C, Ramos-Barbon D, Jack D, Piggott S, Owen R, Higgins M, Kramer B. Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium. Respir Res 2010, 11:135. 10.1186/1465-9921-11-135, 2964613, 20920365.
23. Magnussen H, Verkindre C, Jack D, Jadayel D, Henley M, Woessner R, Higgins M, Kramer B. Indacaterol once-daily is equally effective dosed in the evening or morning in COPD. Respir Med 2010, 104:1869-1876. 10.1016/j.rmed.2010.08.010, 20850959.
24. Chapman KR, Rennard SI, Dogra A, Owen R, Lassen C, Kramer B. Long-term safety and efficacy of indacaterol, a long-acting ß2-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest 2011, 140:68-75. 10.1378/chest.10-1830, 21349928.
25. Renard D, Looby M, Kramer B, Lawrence D, Morris D, Stanski DR. Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches. Respir Res 2011, 12:54. 10.1186/1465-9921-12-54, 3102616, 21518459.
26. Cooper CB. Airflow obstruction and exercise. Respir Med 2009, 103:325-334. 10.1016/j.rmed.2008.10.026, 19071004.
27. Hanania NA, Donohue JF. Pharmacologic interventions in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007, 4:526-534. 10.1513/pats.200701-016FM, 17878465.
28. Malerba M, Radaeli A, Morjaria JB. Therapeutic potential for novel untra long-acting ß2-agonists in the management of COPD: biological and pharmacological aspects. Drug Discov Today 2012, 17:496-504. 10.1016/j.drudis.2011.11.002, 22119310.
29. Fuso L, Mores N, Valente S, Malerba M, Montuschi P. Long-acting beta-agonists and their association with inhaled corticosteroids in COPD. Curr Med Chem 2013, Epub ahead of print.
30. O'Donnell DE, Casaburi R, Vincken W, Puente-Maestu L, Swales J, Lawrence D, Kramer B. Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. Respir Med 2011, 105:1030-1036. 10.1016/j.rmed.2011.03.014, 21498063.
31. Beeh KM, Wagner F, Khindri S, Drollmann AF. Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD. COPD 2011, 8:340-345. 10.3109/15412555.2011.594464, 21793716.